Research progress of RNA editing enzyme ADAR1 in tumor immunity of prostate cancer

doi:10.3760/cma.j.cn441417-20250318-21001

Abstract

Abstract:

Adenosine deaminase acting on RNA 1 (ADAR1) has attracted much attention in the field of cancer, including prostate cancer. As the first identified A-to-I RNA editing enzyme (converting adenosine to inosine), ADAR1 is increasingly being studied in the context of tumor immune evasion. Therefore, this article reviews the mechanisms of action of ADAR1 and its role in tumor immunity in prostate cancer, providing a valuable summary for exploring ADAR1 as a potential therapeutic target in the diagnosis and treatment of prostate cancer.

Key words: Prostate cancer, RNA editing enzyme, ADAR1, Tumor immune escape, Progress

摘要： RNA编辑酶腺苷脱氨酶1（adenosine deaminase acting on RNA 1，ADAR1）在肿瘤领域中的研究备受关注，包括前列腺癌。作为第一个被发现的腺苷转变为肌苷（adenosine to inosine，A-to-I）RNA编辑酶，ADAR1在肿瘤免疫逃逸的研究越来越多。因此，本文对ADAR1的作用机制及其在前列腺癌肿瘤免疫作用综述，为挖掘ADAR1在前列腺癌中作为潜在诊治靶点提供有益总结。

关键词: 前列腺癌, RNA编辑酶, ADAR1, 肿瘤免疫逃逸, 进展

Li Xiezhao, Cai Zhiduan, Yuan Yaoji, Zhu Rui, Zhou Zewen, Xu Guibin, Zhao Haibo. Research progress of RNA editing enzyme ADAR1 in tumor immunity of prostate cancer[J]. International Medicine and Health Guidance News, 2025, 31(21): 3522-3525.

李协照蔡志煅袁耀基朱锐周泽文徐桂彬赵海波. RNA编辑酶ADAR1在前列腺癌肿瘤免疫中的研究进展[J]. 国际医药卫生导报, 2025, 31(21): 3522-3525.

References

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024,74(3):229-263. DOI: 10.3322/caac.21834.
[2] Yang JH, Nie Y, Zhao Q, et al. Intracellular localization of differentially regulated RNA-specific adenosine deaminase isoforms in inflammation[J]. J Biol Chem, 2003, 278(46):45833-42. DOI: 10.1074/jbc.M308612200.
[3] Liddicoat BJ, Piskol R, Chalk AM, et al. RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself[J]. Science, 2015, 349(6252):1115-20. DOI: 10.1126/science.aac7049.
[4] Yu Z, Chen T, Cao X. RNA editing by ADAR1 marks dsRNA as "self"[J]. Cell Res, 2015,25(12):1283-1284. DOI: 10.1038/cr.2015.135.
[5] Xu LD, Öhman M. ADAR1 Editing and its role in cancer[J]. Genes, 2018, 10(1): 12. DOI: 10.3390/genes10010012.
[6] Zhang J, Dang F, Ren J, et al. Biochemical aspects of PD-L1 regulation in cancer immunotherapy[J]. Trends Biochem Sci, 2018, 43(12):1014-1032. DOI: 10.1016/j.tibs.2018.09.004.
[7] Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade[J]. Nat Rev Immunol, 2020, 20(1):25-39. DOI: 10.1038/s41577-019-0218-4.
[8] Mandai M, Hamanishi J, Abiko K, et al. Dual faces of IFNγ in cancer progression: a role of PD-L1 Induction in the determination of pro-and antitumor immunity[J]. Clin Cancer Res, 2016, 22(10):2329-2334. DOI: 10.1158/1078-0432.CCR-16-0224.
[9] Abiko K, Matsumura N, Hamanishi J, et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer[J]. Br J Cancer, 2015, 112(9):1501-1509. DOI: 10.1038/bjc.2015.101.
[10] Garcia-Diaz A, Shin DS, Moreno BH, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression[J]. Cell Rep, 2017, 19(6):1189-1201. DOI: 10.1016/j.celrep.2017.04.031.
[11] Mimura K, Teh JL, Okayama H, et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer[J]. Cancer Sci, 2018, 109(1):43-53. DOI: 10.1111/cas.13424.
[12] Qian J, Wang C, Wang B, et al. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy[J]. J Neuroinflammation, 2018, 15(1):290. DOI: 10.1186/s12974-018-1330-2.
[13] Wu B, Peisley A, Richards C, et al. Structural basis for dsRNA recognition, filament formation, and antiviral signal activation by MDA5[J]. Cell, 2013, 152(1-2):276-89. DOI: 10.1016/j.cell.2012.11.048.
[14] Broquet AH, Hirata Y, McAllister CS, et al. RIG-I/MDA5/MAVS are required to signal a protective IFN response in rotavirus-infected intestinal epithelium[J]. J Immunol, 2011, 186(3):1618-1626. DOI: 10.4049/jimmunol.1002862.
[15] Zamanian-Daryoush M, Mogensen TH, DiDonato JA, et al. NF-kappaB activation by double-stranded-RNA-activated protein kinase (PKR) is mediated through NF-kappaB-inducing kinase and IkappaB kinase[J]. Mol Cell Biol, 2000, 20(4):1278-1290. DOI: 10.1128/MCB.20.4.1278-1290.2000.
[16] Pichlmair A, Schulz O, Tan CP, et al. Activation of MDA5 requires higher-order RNA structures generated during virus infection[J]. J Virol, 2009, 83(20):10761-10769. DOI: 10.1128/JVI.00770-09.
[17] Hartner JC, Walkley CR, Lu J, et al. ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling[J]. Nat Immunol, 2009,10(1):109-115. DOI: 10.1038/ni.1680.
[18] Mannion NM, Greenwood SM, Young R, et al. The RNA-editing enzyme ADAR1 controls innate immune responses to RNA[J]. Cell Rep, 2014, 9(4):1482-1494. DOI: 10.1016/j.celrep.2014.10.041.
[19] Pestal K, Funk CC, Snyder JM, et al. Isoforms of RNA-editing enzyme ADAR1 independently control nucleic acid sensor MDA5-driven autoimmunity and multi-organ development[J]. Immunity, 2015, 43(5):933-944. DOI: 10.1016/j.immuni.2015.11.001.
[20] Ishizuka JJ, Manguso RT, Cheruiyot CK, et al. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade[J]. Nature, 2019,565(7737):43-48. DOI: 10.1038/s41586-018-0768-9.
[21] Kung CP, Maggi LB, Weber JD. The role of RNA editing in cancer development and metabolic disorders[J]. Front Endocrinol (Lausanne), 2018, 9:762. DOI: 10.3389/fendo.2018.00762.
[22] Jiang Q, Crews LA, Barrett CL, et al. ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia[J]. Proc Natl Acad Sci USA, 2013,110(3):1041-1046. DOI: 10.1073/pnas.1213021110.
[23] Xufeng R, Nie D, Yang Q, et al. RNA editing enzyme ADAR1 is required for early T cell development[J]. Blood Sci, 2020, 2(1):27-32. DOI: 10.1097/BS9.0000000000000039.
[24] Young AA, Bohlin HE, Pierce JR, et al. Suppression of double-stranded RNA sensing in cancer: molecular mechanisms and therapeutic potential[J]. Biochem Soc Trans, 2024, 52(5):2035-2045. DOI: 10.1042/BST20230727.
[25] Gannon HS, Zou T, Kiessling MK, et al. Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells[J]. Nat Commun, 2018, 9(1):5450. DOI: 10.1038/s41467-018-07824-4.
[26] Chan TH, Qamra A, Tan KT, et al. ADAR-mediated RNA editing predicts progression and prognosis of gastric cancer[J]. Gastroenterology, 2016, 151(4):637-650.e10. DOI: 10.1053/j.gastro.2016.06.043.
[27] Taverna G , Grizzi F , Melegari S , et al. ADAR1 is highly expressed in primary prostate cancer and correlated with CD8+ T-lymphocytes density[J]. European Urology Supplements, 2018, 17(2):e86.DOI:10.1016/S1569-9056(18)30912-6.
[28] Wang X, Li J, Zhu Y, et al. Targeting ADAR1 with a small molecule for the treatment of prostate cancer[J]. Nat Cancer, 2025, 6(3):474-492. DOI: 10.1038/s43018-025-00907-4.